medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2015, Number 3

<< Back Next >>

Ann Hepatol 2015; 14 (3)

Mycophenolic acid induces apoptosis of hepatic stellate cells in an in vitro model of HCV

Best J, Zahn A, Beilfuß A, Sydor S, Fingas C, Jan-Peter Sowa, Anastasiou O, Cicinnati V, Gerken G, Canbay A, Bechmann LP

Language: English
References: 20
Page: 396-403
PDF size: 177.87 Kb.


ABSTRACT

Introduction. Hepatitis C virus (HCV) infection is an important risk factor for the development of liver fibrosis and progression to cirrhosis. Liver transplantation as terminal treatment option for liver disease requires life-long immunosuppression. However, immunomodulatory therapy may promote reinfection and renewed fibrogenesis. Immunosupressive agents may also affect the life cycle of hepatic stellate cells (HSC), the main source of extracellular matrix. We thus aimed to characterize the effects of three common immunosuppressive agents on HSC apoptosis with or without engulfment of HCV infected apoptotic bodies. Material and methods. LX2 cells were incubated with three different immunosuppressants (rapamycine, mycophenolic acid or cyclosporine A) and co-incubated for 24 and 48 h with apoptotic bodies (AB), produced from Huh7 cells or from Con1 cells (Huh7-cells containing a subgenomic HCV replicon). The engulfment of AB was confirmed by immunofluorescence staining. HSC viability, apoptosis rate and expression of profibrogenic and proapoptotic genes were quantified. Results. In LX2 cells that engulfed Con1 AB, the treatment with mycophenolic acid induced HSC apoptosis and reduced collagen 1alpha 1 expression compared to cylosporine A or rapamycine treatment. In conclusion mycophenolic acid is a potent inducer of HSC apoptosis and attenuates HSC activation and consecutively fibrogenesis in HCV infection. Translational studies will need to confirm these mono-culture results in vivo.


REFERENCES

  1. Asselah T, Bieche I, Sabbagh A, Bedossa P, Moreau R, Valla D, Vidaud M, et al. Gene expression and hepatitis C virus infection. Gut 2009:58:846-58. doi: gut.2008.166348 [pii] 10.1136/gut.2008.166348.

  2. Coilly A, Roche B, Samuel D. Current management and perspectives for HCV recurrence after liver transplantation. Liver Int 2013; 33(Suppl. 1): 56-62. doi: 10.1111/liv.12062.

  3. Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 2011; 25: 195-206. doi: 10.1016/j.bpg.2011.02.005.

  4. Puche JE, Saiman Y, Friedman SL. Hepatic stellate cells and liver fibrosis. Compr Physiol 2013; 3: 1473-92. doi: 10.1002/cphy.c120035.

  5. Canbay A, Feldstein AE, Higuchi H, Werneburg N, Grambihler A, Bronk SF, Gores GJ. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology 2003; 38: 1188-98. doi: 10.1053/ jhep.2003.50472 S0270913903008760 [pii].

  6. Xu L, Hui AY, Albanis E, Arthur MJ, O’Byrne SM, Blaner WS, Mukherjee P, et al. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 2005; 54: 142-51. doi: 10.1136/gut.2004.042127.

  7. Gieseler RK, Marquitan G, Schlattjan M, Sowa JP, Bechmann LP, Timm J, Roggendorf M, et al. Hepatocyte apoptotic bodies encasing nonstructural HCV proteins amplify hepatic stellate cell activation: implications for chronic hepatitis C. J Viral Hepat 2011; 18: 760-7. doi: JVH1362 [pii] 10.1111/j.1365-2893.2010.01362.x. 403 Mycophenolic acid induces apoptosis of hepatic stellate cells in an in vitro model of HCV. , 2015; 14 (3): 396-403

  8. Taimr P, Higuchi H, Kocova E, Rippe RA, Friedman S, Gores GJ. Activated stellate cells express the TRAIL receptor-2/ death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology 2003; 37: 87-95. doi: 10.1053/ jhep.2003.50002.

  9. Yu J, Zhang L. PUMA, a potent killer with or without p53. Oncogene 2008; 27(Suppl. 1): S71-83. doi: 10.1038/ onc.2009.45.

  10. Greupink R, Bakker HI, Reker-Smit C, van Loenen- Weemaes AM, Kok RJ, Meijer DK, Beljaars L, et al. Studies on the targeted delivery of the antifibrogenic compound mycophenolic acid to the hepatic stellate cell. J Hepatol 2005; 43: 884-92. doi: 10.1016/j.jhep.2005.04.014.

  11. Andriulli A, Di Marco V, Margaglione M, Ippolito AM, Fattovich G, Smedile A, Valvano MR, et al. Identification of naive HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin. J Hepatol 2014; 60: 16-21. doi: S0168-8278(13)00594- 1 [pii] 10.1016/j.jhep.2013.07.040.

  12. Wells MM, Roth LS, Marotta P, Levstik M, Mason AL, Bain VG, Chandok N, et al. Increased duration of dual pegylated interferon and ribavirin therapy for genotype 1 hepatitis C post-liver transplantation increases sustained virologic response: a retrospective review. Saudi J Gastroenterol 2013; 19: 223-9. doi: SaudiJGastroenterol_ 2013_19_5_223_118133 [pii] 10.4103/1319-3767.118133.

  13. Coilly A, Roche B, Duclos-Vallee JC, Samuel D. Management of HCV transplant patients with triple therapy. Liver Int 2014; 34(Suppl. 1): 46-52. doi: 10.1111/liv.12406.

  14. Younossi ZM, Singer ME, Mir HM, Henry L, Hunt S. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. J Hepatol 2014; 60: 530-7. doi: 10.1016/j.jhep.2013.11.009.

  15. Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, Symonds WT, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014; 383: 515-23. doi: 10.1016/S0140-6736(13)62121-2.

  16. Fontana RJ, Hughes EA, Bifano M, Appelman H, Dimitrova D, Hindes R, Symonds WT. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant 2013; 13: 1601-5. doi: 10.1111/ajt.12209.

  17. Kornberg A, Kupper B, Wilberg J, Tannapfel A, Thrum K, Barthel E, Hommann M, et al. Conversion to mycophenolate mofetil for modulating recurrent hepatitis C in liver transplant recipients. Transpl Infect Dis 2007; 9: 295-301. doi: TID228 [pii] 10.1111/j.1399-3062.2007.00228.x.

  18. Badid C, Vincent M, McGregor B, Melin M, Hadj-Aissa A, Veysseyre C, Hartmann DJ, et al. Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney. Kidney Int 2000; 58: 51-61. doi: kid140 [pii] 10.1046/j.1523-1755.2000.00140.x.

  19. Bridle KR, Popa C, Morgan ML, Sobbe AL, Clouston AD, Fletcher LM, Crawford DH. Rapamycin inhibits hepatic fibrosis in rats by attenuating multiple profibrogenic pathways. Liver Transpl 2009; 15: 1315-24. doi: 10.1002/ lt.21804.

  20. Firpi RJ, Soldevila-Pico C, Morelli GG, Cabrera R, Levy C, Clark VC, Suman A, et al. The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study. Dig Dis Sci 2010; 55: 196-203. doi: 10.1007/ s10620-009-0981-3.




2020     |     www.medigraphic.com